Laminin-111 protein therapy after disease onset slows muscle disease in a mouse model of laminin-α2 related congenital muscular dystrophy.

Saved in:
Bibliographic Details
Title: Laminin-111 protein therapy after disease onset slows muscle disease in a mouse model of laminin-α2 related congenital muscular dystrophy.
Authors: Barraza-Flores P; Department of Pharmacology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA., Bukovec KE; Department of Human Nutrition, Foods, and Exercise, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA., Dagda M; Department of Pharmacology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA., Conner BW; Department of Pharmacology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA., Oliveira-Santos A; Department of Pharmacology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA., Grange RW; Department of Human Nutrition, Foods, and Exercise, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA., Burkin DJ; Department of Pharmacology, Reno School of Medicine, University of Nevada, Reno, NV 89557, USA.
Source: Human molecular genetics [Hum Mol Genet] 2020 Aug 03; Vol. 29 (13), pp. 2162-2170.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: IRL Press at Oxford University Press Country of Publication: England NLM ID: 9208958 Publication Model: Print Cited Medium: Internet ISSN: 1460-2083 (Electronic) Linking ISSN: 09646906 NLM ISO Abbreviation: Hum Mol Genet Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1460-2083
DOI:10.1093/hmg/ddaa104